A Review of the Opioid System in Cancer Patients and Preliminary Results of Opioid Antagonists in the Treatment of Human Neoplasms
Reference54 articles.
1. Abou-Hissa H., and Tejwani G.A. (1991) Antitumor activity of naltrexone and correlation with steroid hormone receptors. Biochem. Biophys. Res. Commun. 175, 625–630.
2. Arakawa K., Akami T., Okamoto M., Oka T., Nagase H., and Matsumoto S. (1992) The immunosuppressive effect of delta-opioid receptor antagonist on rat renal allograft survival. Transplantation 53, 951–953.
3. Barni S., Lissoni P., Rovelli F., Crispino S., Paolorossi F., Esposti D., et al. (1988) Alteration of opioid peptide circadian rhythm in cancer patients. Tumori 74, 357–360.
4. Bihari B. (1995) Efficacy of low-dose naltrexone as an immune stabilizing agent for the treatment of HIV/AIDS. AIDS. Patient Care 9, 3 (abstract).
5. Blattman J.N., and Greenberg P.D. (2004) Cancer immunotherapy: a treatment for the masses. Science 305, 200–205.